Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
(18h)
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
(19h)
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
(20h)
Cardiac medtech HeartBeam drops CEO in restructuring aimed at global ECG platform push
(21h)
Chutes & Ladders—EMD Serono taps in new commercial strategy head
(1d)
The deal before the deal
(1d)
Fosun Pharma plots global push beyond oncology, fueled by multi-asset Alzheimer’s strategy
(1d)
Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision
(1d)
Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect
(1d)
FDA drops blood pressure device enforcement against Whoop
(2d)
BIO 2026: How a gut feeling transformed cancer treatment forever
(2d)
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery
(2d)
Spurned by FDA, Passage Bio finds exit through merger with Remix
(2d)
With $15M discovery deal, Boehringer becomes latest Big Pharma to buy into Immunai’s AI platform
(2d)
Icon names Microsoft tech partner as Q1 results grow analyst confidence
(2d)
Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO chief
(2d)
Puerto Rico makes its case as a biotech manufacturing hub
(2d)
RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic
(2d)
Novartis pays Antares $105M to illuminate undruggable cancer targets
(2d)
Abbott pens blood-based Alzheimer's testing pact with ALZpath
(2d)
BioPharma Dive
At BIO, tension over China biotech deal regulation looms
(17h)
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
(19h)
On second try, Acadia drug gets nod from European regulators
(19h)
Remix to go public in reverse merger with once high-flying Passage Bio
(1d)
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
(1d)
Antares gets $105M from Novartis for new cancer drugs
(1d)
Ionis, with new FDA nod, hits a ‘commercial inflection point’
(2d)
Investors pour $115M into RQ Bio in search of a preventive flu drug
(2d)
To Wall Street, psychedelics biotechs are more teammates than rivals
(2d)
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
(2d)
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
(2d)
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
(3d)
How Kardigan spun deal leftovers into a $400M IPO
(3d)
HHS, responding to China’s rise, moves to fast-track early drug research
(3d)
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
(3d)
Hospitals irate after Eli Lilly follows through on 340B ultimatum
(3d)
Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection
(4d)
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
(4d)
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
(4d)
Bionyra brings in $165M for next-generation immune drugs
(4d)
Endpoints News
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
(10h)
FDA advisory panels are back, with new meetings for Replimune, Capricor
(14h)
Akeso pushes back on ASCO questioning of lung cancer drug
(17h)
EU probes Sanofi for alleged smear campaign against rival flu vaccine
(17h)
Lycia raises $75M for food allergy and Graves’ disease
(18h)
EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos
(19h)
How Epicrispr is using 'digital twins' to study a muscle disease therapy
(20h)
Michael Gilman retires as Arrakis CEO; Daniel Skovronsky joins Illumina's board of directors
(21h)
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
(1d)
RTW’s Rod Wong on how China has (and hasn’t) changed his firm’s investments
(1d)
Recordati licenses Ionis drug; Vaxart's BARDA funding is cut
(1d)
Merck KGaA makes largest deal in a decade in $11.3B buy for Bio-Techne
(1d)
Retracted paper on timing of cancer therapy hands ammunition to anti-China lobby
(1d)
Achieve Life Sciences gets a CRL; UPS invests $48M in healthcare logistics
(1d)
Compounder Olympia Pharmaceuticals eyes peptide opportunity
(1d)
Autoimmune disease company Oblenio Bio clinches $62M in Series B
(2d)
How GSK's new CEO lined up a major buyout to start his time at the top
(2d)
Ionis wins FDA label expansion to reduce triglycerides, pancreatitis
(2d)
FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer
(2d)
Remix does reverse merger with Passage Bio for mRNA degrader
(2d)
BioSpace
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy
(13h)
BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review
(19h)
The hidden cost of FDA unpredictability
(19h)
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
(20h)
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
(20h)
Merck KgaA inks $11B Bio-Techne buyout to expand into cell therapy production
(20h)
BIO 2026: Forget dual track—biopharma deals are more complex than ever
(1d)
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
(1d)
The Golden Triangle and the gaps: Rethinking UK biotech
(1d)
Revolution’s second RAS blocker doubles chemo response rate in pancreatic cancer
(1d)
Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
(1d)
Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer
(1d)
FDA’s uniQure, REGENXBIO reversals could bolster other near-term rare disease applications
(1d)
10 companies hiring in San Francisco, South San Francisco (plus a few in Brisbane, San Rafael)
(2d)
Labs see rising demand for nitrosamine, topical performance and microbiome testing
(2d)
Jubilant draws FDA rebuke for delayed mold investigation and quality unit lapses
(2d)
ADC Therapeutics lays off staff after 27 patient deaths mar Zynlonta readout
(2d)
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy
(2d)
BIO CEO Crowley, DOD doctor Overton are top candidates for FDA commissioner: RBC
(2d)
FDA hiring 2,200 people to staff up after last year’s DOGE cuts
(2d)
STAT News
BIO 2026: AI, federal policy impacts, and general vibes
(15h)
Up and down the ladder: The latest comings and goings
(17h)
988’s LGBTQ+ hotline to relaunch this year. But the group that helped start it might be excluded
(18h)
Embryo editing advances reignite ethical debates
(19h)
We’re reading about a bill to overhaul the 340B program, a new FDA commish candidate, and more
(19h)
European antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine
(20h)
Supreme Court rules in weedkiller cancer case
(21h)
What is pulmonary hypertension and why would a new GLP-1 help?
(1d)
Joseph Fraumeni Jr., pioneering cancer genetics researcher, devoted his life to families like mine
(1d)
‘The Hot Zone’ led me to work with Ebola patients. Now I have mixed feelings about the book
(1d)
Jails are the frontline in fielding dangerous new type of drug withdrawal
(1d)
New ACIP charter broadens criteria for members, calls for review of alternatives to vaccines
(1d)
At BIO 2026, industry wrestled with Washington politics, and making AI work better
(1d)
The mysterious case of Eli Lilly’s obesity drug
(1d)
Cassidy proposes bill to rein in 340B drug discount program
(1d)
Supreme Court ruling blocks thousands of lawsuits against maker of Roundup weedkiller
(1d)
Proposed CDC science office could tighten political control at agency
(1d)
Democrats press White House on who got special access to Eli Lilly’s new obesity drug
(1d)
Next-gen CRISPR tools improve editing accuracy in embryos, but also stoke ethical concerns
(1d)
The China debate gets louder in Washington
(1d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(18h)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(2mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(2mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(2mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(3mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(3mo)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(3mo)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(3mo)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(3mo)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(3mo)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(3mo)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(3mo)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(3mo)
Drug Channels
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(22h)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(4d)
The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy
(1w)
Drug Channels News Roundup, Mid-June 2026: Biosimilar Development Barriers, Hospital Specialty Pharmacy Growth, Medicaid Incentives, Drug Pricing Tradeoffs, and the Prescription-Filling Process
(1w)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
(1w)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
(1w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care (rerun)
(2w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care (rerun)
(2w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(2w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(2w)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update (rerun)
(2w)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update (rerun)
(2w)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments (rerun)
(2w)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments (rerun)
(2w)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)
(3w)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)
(3w)
Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight
(3w)
Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight
(3w)
The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs
(3w)
The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs
(3w)
European Biotechnology Magazine
ProQR validates RNA editing platform and raises $59.2m
(1d)
Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy
(1d)
ADC Therapeutics cuts 17% of staff after safety setback
(2d)
Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine
(2d)
Leyden Labs adds €40m for intranasal flu prevention
(2d)
RQ Bio raises $115m for long-acting flu antibody
(2d)
Thalia buys Sanmirna, becomes a clinical-stage RNA company
(3d)
Merck launches build-to-buy Saturnus Bio with $50m
(3d)
TRIMTECH extends seed round to $47M for protein degradation drugs
(3d)
Indivumed, ready to set sail to the clinic
(4d)
After FDA rejection, Sanofi’s BTK inhibitor wins EU approval
(4d)
Can Sanofi buy its way into in vivo CAR-T?
(4d)
Bionyra launches with $165m, France’s largest biotech Series A
(4d)
BioArctic signs potential $1bn Alzheimers research deal with Eli Lilly
(5d)
Theranostics as potential novel therapeutic pillar in oncology
(5d)
Novo Nordisk Foundation launches €60.2m European incubator for cardiometabolic drug discovery
(1w)
Jazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCellera
(1w)
F2G’s oral antifungal clears Phase III hurdle
(1w)
FDA opens path for uniQure’s Huntington’s gene therapy filing
(1w)
AI: Breaking barriers in CNS research
(1w)
Drug Hunter
May 2026
(13h)
MRTX1719
(1d)
cleminorexton
(2d)
fluoxetine
(3d)
An ADC Primer for Medicinal Chemists
(4d)
CID-078
(1w)
zasocitinib (TAK-279/NDI-034858)
(1w)
Target- and Ligase-First Use of DCAF16 for TPD
(1w)
Topological Polar Surface Area Cheat Sheet
(1w)
irafamdastat (BMS-986368)
(2w)
Module 5, Section 1: Property-Based Design
(2w)
baxdrostat
(2w)
Locking the Sec61 Gate to Corral Disease
(2w)
linerixibat
(2w)
NVP-INE963
(2w)
sonrotoclax (BGB-11417)
(3w)
Module 4 Quiz
(3w)
Brushstrokes of Biology: Cell Painting for Mechanism of Action
(3w)
tazemetostat
(3w)
acoziborole
(3w)
Labiotech.EU
“It’s time to Act”: EU biotech to undergo major changes
(19h)
De-risking neurology drug development with better mouse models
(1d)
How human-first datasets are reshaping AI drug discovery
(2d)
Roche, a company built on oncology and diagnostics reinventing its pipeline
(2d)
Bronchiectasis treatment after brensocatib: where the field goes next
(3d)
8 of the most expensive drugs in biopharma: Unraveling the costliest medications
(4d)
The Naming Patterns Behind 12,000 Biotech Companies
(1w)
BIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler
(1w)
Eight in vivo CAR T biotechs to follow closely
(1w)
Viral vector production: How CDMOs influence late-stage development success
(2w)
New names, new narratives: Why biotechs decide to rebrand
(2w)
DIY biology experiments: how far has the rabbit hole gone?
(2w)
Advancing corticosteroids and hormonal therapies for supply and scale
(2w)
How Daiichi Sankyo aims to become a top five oncology player by 2035
(2w)
Beyond amyloid and dopamine: emerging technologies reshaping neurology
(2w)
Pharma in Spain: why global investors and innovators are moving in
(3w)
Top biotech deals in May 2026
(3w)
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(3w)
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(3w)
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
(3w)
Bio IT World
The Spatial Biology Bottleneck: Why AI Models Fail on Complex Tissue & What Actually Fixes It
(1d)
Every Microbiome Tells a Changeable, Computable Story
(3d)
Notes from the Trenches: A Computational Biologist’s View of Drug Discovery’s Digital Revolution
(4d)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
The Invisible Infrastructure: Bio-IT World Panel Warns of a Slow-Motion Crisis in Biomedical Data
(1w)
Microsoft, Ginkgo Collaborate to Demonstrate Lab-in-the-Loop Biology
(2w)
From Automation to Autonomy: How Agentic AI Is Redefining Biopharma’s Digital Workforce
(2w)
Navigating the Perilous Journey from Lab to Market
(2w)
As AI Reshapes Drug Discovery the Lab Remains the Bottleneck
(3w)
Federation Plus Fine Tuning: The Push for Federated Learning Models Continues
(3w)
Trends from the Trenches: AI-Ready Life Sciences Data
(3w)
A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs
(4w)
Immunai, AstraZeneca Expand Partnership, Rancho Biosciences Releases Multi-omics Datasets, Dotmatics AI Co-Scientist
(4w)
Insilico Medicine, Human Longevity Partner for Longevity Foundation Model
(4w)
Bio-IT World VIP Conference: Exploring Breadth vs. Depth
(1mo)
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
(1mo)
At Bio-IT World's 25th Anniversary, Rare Disease Takes Center Stage
(1mo)
Best New Products at Bio-IT World From BioTeam, Dantech, Rancho
(1mo)
GEN News
Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics
(13h)
Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
(16h)
Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model
(16h)
Nipah and Hendra Viruses: Antibody Cocktail Provides Complete Protection in Hamster Model
(17h)
Circio’s circVec and Tcelltech’s nanoSMAR Technologies Combined to Generate Nextgen In vivo CAR-T and TCR-T Cells
(20h)
AI Framework Surfaces New CAR T Target with Multi‑Cancer Potential
(1d)
Antibiotics Trigger Protein Sharing Among Bacteria, Aiding Persister Cells
(1d)
Merck KGaA to Acquire Bio-Techne for $11.3B, Expanding Life Science Tools Presence
(1d)
BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development
(1d)
InduPro Licenses Lonza’s Linker Payload Technologies and Bioconjugation Platforms
(1d)
Drug Targets LDL Receptor Pathway to Control Cholesterol
(2d)
First-in-Human Stem Cell Therapy Trial for Huntington’s Disease Begins at UCI Health
(2d)
BIO 2026: CEO Calls for U.S. Biotech Urgency and International Competitiveness
(2d)
Novel Feeder Cell Line Dramatically Expands NK Cell Production
(2d)
Recoded E. coli Promises More Scalable Weight Loss Drug Production
(2d)
Scaling Stem-Cell Manufacturing for Therapies
(2d)
WHO Selects NIBRT as Training Hub to Help LMICs Build Biopharma Capacity
(2d)
Medra Launches Reasoning Layer for Drug Discovery Robotics
(2d)
Spotlight on RNA Therapeutics
(2d)
California Still Golden Despite Job Losses: Industry Group
(3d)
Cure Today
Without Cancer I Am Practicing Self-Care
(1d)
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
(2d)
The Whole Person: How Susan Yaguda Is Redefining Cancer Care
(2d)
FDA Approves Ibrance Combo for Maintenance Treatment of HR-Positive, HER2-Positive Metastatic Breast Cancer
(2d)
Living With Cancer: What the Mariana Trench and Cancer Have in Common
(2d)
Nurse Navigator Provides Compassionate Care Beyond Diagnosis
(3d)
FDA Expands Tecelera Approval to Include Patients as Young as 12 With Advanced Synovial Sarcoma
(3d)
When a Routine Cancer Screening Stops Being Routine
(3d)
Called to Care: Dr. Jessica Scerbo on What It Really Means to Treat Children With Cancer
(4d)
Top 5 Takeaways From EHA 2026 That Patients Should Know
(4d)
Of Course I Worry: Living With Uncertainty Six Years After Remission
(4d)
An Oncology Physical Therapist Explains Why Movement Matters Most During Cancer Treatment
(6d)
Every Holiday, A Milestone: My Sister's 11-Year Cancer Journey
(1w)
Oncology Nurse Tammy Zinn on Hope, Heart and 30 Years of Care
(1w)
Oncology Nurse Jill Winther on 3 Decades of Advocacy and Care
(1w)
Scanxiety and Long-term Monitoring Strategies
(1w)
Daily Life Management and Side Effect Monitoring in Patients with ALK-Positive NSCLC
(1w)
Tammy Zinn on Replacing Fear With Hope in Oncology Nursing
(1w)
35 Years In, Oncology Nurse Reflects on Advocacy and the "Why"
(1w)
The Tattoo That Carried Me Through Cancer
(1w)
Contract Pharma
Reducing Risk in Pharma Product Transfers
(15h)
Adragos Pharma Kawagoe, Towa Pharmaceutical Ink Strategic Supply Pact
(17h)
AI in Biologics CDMO Workflows: A BIO Conversation with Lonza
(17h)
The Friday Brief for June 26, 2026: BIO 2026 Recap
(18h)
Enzene Premieres Nex Partnership Program at BIO 2026
(1d)
Best Practices for Solving Complex Formulation Challenges While Maintaining Speed Through the Lifecycle
(1d)
From Potential to Practical at DIA 2026: A Three-Part Series on Unlocking AI’s Role in Modern Clinical Trials
(1d)
By the Numbers: Top 10 Pharma & Biopharma Companies
(1d)
Merck KGaA to Acquire Bio-Techne for $11.3B
(1d)
DDL Appoints Jennifer Riter as Vice President of Analytical Testing Services
(1d)
A Guide to Filtration Sterilization, From Microbial Retention Testing to Custom Validations
(1d)
Agilent Completes Acquisition of Biocare Medical
(1d)
Shilpa Biologicals Commissions Integrated ADC Drug Substance GMP Manufacturing Facilities
(1d)
SK pharmteco Launches SKyvec Proprietary Multimodal Viral Vector Platform
(2d)
Julie Kim Takes Helm as Takeda CEO
(2d)
Circio, Tcelltech Enter CAR-T Cell Therapy Research Collaboration
(2d)
Abbisko Therapeutics, Lilly Expand R&D Alliance
(2d)
Combotope Therapeutics, Boehringer Ingelheim Partner on Tumor-Selective Antibodies for Cancer
(2d)
TELEO Capital Acquires Applied Materials’ Pharmaceutical Manufacturing Intelligence Platform
(3d)
Sartorius, LFB Biomanufacturing Expand Collaboration
(3d)
Pharma Times
Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial
(2d)
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer
(2d)
Lundbeck to present new Vyepti and bocunebart data at EAN 2026
(2d)
Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
(3d)
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
(4d)
Cenrifki approved in EU for secondary progressive multiple sclerosis
(4d)
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
(2w)
Anocca doses first patients with precision TCR‑T therapy
(2w)
Connecta launches phase 2a trial of neuroplasticity modulator
(2w)
Aquipta recommended by NICE for acute migraine treatment
(2w)
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
(2w)
Alzecure enters collaboration and with Lilly for Alzheimer’s project
(2w)
Survodutide trial data show targeted visceral and liver fat reductions
(3w)
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
(3w)
European approval enables measles protection with CSL’s immunoglobulin Privigen
(3w)
JJP Biologics reports positive interim phase 1b data for nebaprubart
(3w)
Immunotherapy boost can spare more bladder cancer patients major surgery
(3w)
Deep Science Ventures and MDC partner to accelerate brain treatments
(3w)
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
(3w)
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
(1mo)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(1w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(1w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(1w)
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
(1w)
The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate
(1w)
Leveraging Technology to Navigate the New Era of Continuous Organ Distribution
(1w)
InStride Raises $30M to Scale Pediatric Mental Health Support
(1w)
New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug
(1w)
What’s Flowing Beneath the World Cup: How Verily’s Wastewater Monitoring Could Catch the Next Outbreak
(1w)
The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design
(1w)
Healthcare Access Depends on Infrastructure: Why Rural Communities Can’t Afford Fragmentation
(1w)
Natural Selection Will Weed Out the Weak in the Race to Autonomous Healthcare
(1w)
Healthcare AI Beyond the Buzzwords: Ambient, Generative, and Agentic Explained
(1w)
Multicare CFO: Decades of CMS Underpayment is Creating an Unfair Two-Tiered System
(2w)
Elevance Health’s 3 Key Priorities for AI
(2w)
Lilly’s Newly Acquired Drug Shows Promise as Next-Gen Blood Cancer Med
(2w)
Don’t Leave Healthcare’s Greatest Asset Behind on the Road to Interoperability
(2w)
Where Healthcare Data Systems Fail and How to Build Them Better
(2w)
The FDA Opened the Door For Rare Disease Patients — Here’s What It Takes to Walk Through It
(2w)
Why One in Four Americans Is Walking Away from Healthcare
(2w)
Chemical & Engineering News
Supreme Court sides with Bayer in landmark pesticide-labeling case
(13h)
A new method measures PFAS-based microplastics
(15h)
Policy Watch: HHS moves to keep more drug trials in the US
(16h)
Ancient Martian rocks preserve complex organic carbon
(17h)
Membrane-based separations for more efficient crude oil refining
(19h)
C&EN weekly chemistry news quiz, June 26
(21h)
Self-driving labs are changing how chemists work
(1d)
What happens when you edit an essential gene in human embryos?
(1d)
Merck KGaA to buy Bio-Techne for around $11 billion
(1d)
Chemistry in Pictures: Quantum carbenes
(1d)
Here’s what pharmas and investors are looking for at BIO
(1d)
ACS Board June 2026 meeting outcomes
(2d)
Nitrosamines are catalyzing a sea change in pharma quality control
(2d)
Uncovered: The road to sustainable rare earths runs through Brazil
(2d)
Scientists peek into the Pink Planet’s atmosphere
(2d)
US gives AI firm $500 million for electronic-chemical discovery
(3d)
US chemistry graduate programs scale back
(3d)
Why the Reflecting Pool keeps turning green
(3d)
Business Watch: Evonik to cut 3,200 jobs; AbbVie buys Apogee for almost $11 billion
(3d)
‘We’re prepared for whatever the FDA wants’: A vaccine developer gets back on track
(3d)
The Pharma Letter
Why has the need in gMG become so severe, and how has understanding evolved?
(16h)
EC opens formal antitrust investigation on Sanofi
(16h)
June 2026 batch of EMA/CHMP recommendations
(16h)
Elixirgen and Nippon Shinyaku ink option agreement on DMD
(19h)
EC approves Inaqovi combination for AML patients ineligible for intensive chemotherapy
(19h)
Definium raises $805 million after positive Phase III depression data
(19h)
Menarini reports data from the Phase III SENTRY trial of selinexor
(21h)
NHS A&E testing finds 1,900 undiagnosed HIV cases
(22h)
Candel hires AstraZeneca executive to lead commercial plans
(22h)
NICE recommends MSD’s Keytruda for LAAC in adults
(23h)
CNX and Legacy set July US relaunch for Ethyol
(23h)
Otsuka posts positive Phase IIIb data for novel ADHD therapy
(23h)
Galen’s Penthrox inhaler licensed for UK children in trauma pain -
(1d)
Merck KGaA to acquire Bio-Techne for $11.3B cash -
(1d)
Boehringer Ingelheim teams with Immunai to find T-cell targets using AI -
(1d)
Recordati gains rights to Ionis’AxD drug zilganersen -
(1d)
MHRA grants marketing authorization for Ipsen’s Bylvay -
(1d)
Moderna outlines next phase of mRNA expansion beyond vaccines -
(1d)
FDA expands Pfizer’s Ibrance into HER2-positive breast cancer maintenance -
(1d)
Vaxxirna launches to advance next-gen RNA vaccines -
(1d)
Targeted Oncology
NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care
(1d)
Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera
(2d)
Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC
(2d)
FDA Approves Sacituzumab Govitecan for First-Line TNBC Treatment
(2d)
KOMET-007: Bringing Menin Inhibition Into Frontline AML Care
(2d)
FDA Approves Palbociclib Plus Anti-HER2 and Endocrine Therapy as Maintenance in Breast Cancer
(2d)
Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma
(2d)
Dr Ahn: Exploring Treatment-Free Remissions With Pirtobrutinib in CLL
(2d)
Zanzalintinib Plus Atezolizumab Misses OS End Point in Liver Metastasis–Free mCRC Subgroup
(3d)
Florez Highlights Overlooked Needs of Young Patients, Women With Lung Cancer
(3d)
FDA Grants Full Approval of Afami-Cel in Synovial Sarcoma, Expands Indication to 12 and Older
(3d)
Sigvotatug Vedotin Misses OS End Point in Phase 3 NSCLC Trial
(3d)
Safety, Functionality, and Overall QOL Considerations in Third-Line KRAS-Mutant CRC
(4d)
ASCO 2026 Lung Cancer Abstracts: Clinical Practice Implications
(4d)
Addressing Unmet Needs in Brain Tumor Care: A Conversation With Raj Singh, MD
(5d)
CRB-701 Shows Antitumor Activity in HNSCC
(5d)
Researchers Track the Memory of Cancer in Lynch Syndrome
(6d)
"You're Home": Why Young Women With Lung Cancer Are Being Missed
(6d)
How Turning to Psychedelics Can Help Patients With Cancer Heal
(7d)
In Vivo Paradigm Aims to ‘Sidestep’ Logistics Problems of CAR T
(1w)
MedWatch
Hims & Hers poised to benefit as insurers pull back on weight-loss drug coverage
(20h)
Demant on track for best quarter since the turn of the millennium
(21h)
GN Hearing CFO to join Danish shipping company
(22h)
US biotech index hits record high, Danske Bank cites several drivers
(23h)
Removing gender and photos from applications led Gubra to gender equality in management
(23h)
Internal EU document: Biotech Act has only limited impact
(1d)
Pfizer cleared in lawsuit over illegal price-fixing
(1d)
Novo Nordisk saw slight decline in prescriptions for Wegovy tablets last week
(1d)
EIFO ready with historic investment in new European fund
(1d)
Eli Lilly to launch weight-loss drugs for Medicare patients starting July 1
(1d)
From mass layoffs to hiring surge: FDA to hire 2,000+
(1d)
Eli Lilly and Bayer support US trade probe into German drug prices
(1d)
Eli Lilly and Bayer support US trade probe into German drug prices
(1d)
Eli Lilly and Bayer support US trade probe into German drug prices
(1d)
Merck acquires Bio-Techne in a deal worth double-digit billions
(1d)
EFPIA warns about drug prices in Europe
(2d)
Trump administration seeks billions for Iran war costs and Ebola response
(2d)
Analyst: A tough challenge lies ahead for Lundbeck's new head of research
(2d)
Strong sales of the Wegovy tablet lead analysts to predict possible upward revision at Novo Nordisk
(2d)
Eli Lilly signs new partnership deal with China's Abbisko
(2d)
In The Pipeline
Speaking Up: Who Is, and Who Isn't
(11h)
Antibody-Drug Conjugates: Not Quite Worked Out Yet
(1d)
Here's a Ligand, Go Design a Protein
(2d)
Machine-Learning Mass Spec Data: Hmmm
(4d)
Covid-19 Vaccinations and the Heart
(2w)
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(2w)
A New Antibiotic Idea From An Old Source
(2w)
Insights Into Idiopathic Pulmonary Fibrosis
(2w)
Unusual Toxicity With a Protein Degrader Molecule
(3w)
The Causes of Long Covid
(3w)
Action! Action Now.
(3w)
The Current Crisis: What's Happening to Science in America
(4w)
Evaluating "Co-Scientist", a New AI Science System
(1mo)
That Methyl Methacrylate Tank
(1mo)
Reading the Labels on Mutant Mice
(1mo)
CYA
(1mo)
Stemming the AI Preprint Flood
(1mo)
A Futuristic Synthesis Indeed
(1mo)
What Success Can Look Like, Darn It
(1mo)
More Vague, But More Useful
(1mo)
Pharmaphorum
Sanofi faces EU investigation over flu shot marketing
(21h)
Moderna shows in vivo CAR-T hand in R&D update
(22h)
Obesity is rising fastest in young adults in England
(1d)
Merck buys life sciences firm Bio-techne in $11.3bn deal
(1d)
Hub-and-spoke firm Osanni raises $190m, and other financings
(1d)
Ibrance cleared in US for 'double-positive' breast cancer
(1d)
Tarek Samad takes on task of delivering on Lundbeck's RD
(1d)
NICE delivers more good news for cervical cancer patients
(1d)
Ionis' Tryngolza claims critical label expansion in US
(2d)
Lilly launches its LillyDirect sales channel in the UK
(2d)
NICE says Libtayo can be used for advanced cervical cancer
(2d)
Bispecific antibody firm Ollin raises $330m in bumper round
(2d)
Astellas Padcev and Gilead's Trodelvy grab key EU approvals
(2d)
UK's RQ Bio raises $115m for flu prevention drug
(3d)
EFPIA report adds to pressures on EU drug pricing policy
(3d)
HHS details plan to regain the US's edge in clinical trials
(3d)
Pfizer's Seagen-derived ADC pipeline suffers a setback
(4d)
MSD's TL1A drug tulisokibart delivers in pivotal IBD trial
(4d)
Sanofi's type 1 diabetes-delaying drug cleared for NHS use
(4d)
CARSgen bags world-first approval for solid tumour CAR-T
(4d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1w)
Webinar: Learn how to accelerate the early stages of drug discovery
(1w)
Therapy enables 89% survival rate in myeloma patients
(1w)
Ulcerative colitis treatment shows best-in-class potential
(1w)
UK patients to benefit from approval of weight loss tablet
(1w)
Vertex presents new data on Casgevy in children
(1w)
DDW Highlights: 16 June 2026
(1w)
LXR inverse agonist shows promise in liver disease
(1w)
Guide: One solution – from R&D, to QC
(1w)
A potentially practice-changing advance in bile duct cancer
(1w)
Webinar: Consolidate multiple assays into a single, comprehensive AVA test
(2w)
JAK inhibitor for VEXAS syndrome gets orphan drug designations
(2w)
Whitepaper: How workflow scheduling software can answer the demands of automated labs
(2w)
PhoreMost advances brain cancer programme to trial
(2w)
Oriva appoints Arbat as CEO, advances endometriosis asset
(2w)
Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar
(2w)
This week in Drug Discovery (8 June – 12 June)
(2w)
Laverock reports positive data from oncology programmes
(2w)
GSK acquires Nuvalent and cancer therapy pipeline
(2w)
HIT Consultant
KLAS Arch Collaborative Releases Clinician EHR Experience 2026 Impact Report
(18h)
Hera Raises $27M to Scale AI-Powered Senior Care Coordination
(18h)
ZS Impact Institute Releases 2026 Future of Health Report: AI and the Consumer-Led Care Revolution
(19h)
Hurone AI Licenses Mayo Clinic’s HOUSES Technology to Scale Personalized Cancer Navigation
(19h)
AMGA 2026 Survey: Provider Compensation Rises 4.3% as Medical Groups Face Sustainability Warning
(19h)
Beyond Chatbots: Agentic AI as the Operating System Transforming Patient Services
(1d)
Houston Methodist Partners with HealthLeap to Launch AI-Driven Clinical Screening Platform
(1d)
xCures Raises $46M to Turn Unstructured EHR Data Into Actionable Clinical Intelligence
(1d)
Upside Secures $20M to Scale AI-Driven Housing Stability Platform for Healthcare
(1d)
Innovaccer and AWS Announce Multi-Year Strategic Collaboration to Scale Agentic AI in Healthcare
(1d)
Healthcare’s Next Software Crisis Will Be a Governance Failure, Not a Technology Failure
(2d)
Assort Health Raises $120M at a $1.2B Valuation to Scale Patient Access AI Agents
(2d)
Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy
(2d)
Cadence Secures $100M, Partners with Duke Health to Scale Chronic Care AI
(2d)
Xella Health Launches with $4.7M to Scale AI-Powered Precision Testing for Women’s Health
(2d)
Oracle Health Partners with Theator to Deliver AI-Native Surgical Video Analytics and Automated EHR Documentation
(2d)
Prosper AI Raises $30M to Scale Patient Access Automation
(3d)
Moving Healthcare AI from Experimental Pilots to Scaled Execution
(3d)
DUOS Acquires Linkwell Health to Expand AI-Powered Health Plan Performance Footprint
(3d)
BrightHeart Secures European CE Mark for B-Right AI Prenatal Ultrasound Platform
(3d)
Insights: Pink Sheet
US Pushing Foreign Countries To Pay More For Drugs: Will It Help Americans?
(10h)
BsUFA IV: Money Can’t Buy Industry Reference Product Exclusivity Determinations
(12h)
US FDA Adcomm Will Review Formerly Rejected Capricor, Replimune Regenerative Medicines
(14h)
Trump Nominates Medicare Director, HHS Power Broker Chris Klomp For Deputy Secretary
(14h)
Pink Sheet Podcast: US FDA’s New Guidance On One-Trial Efficacy Standard And IND Reform Pilot
(16h)
Omeros To Fight Its EU Corner After EMA Rejects US-Approved Yartemlea
(16h)
MaaT Pharma Leans On Expert Panel To Highlight aGvHD ‘Clinical Reality’ After EMA Rejection
(16h)
CSL Faces EU Withdrawal Of Tavneos After EMA Finds Study Data Unreliable
(16h)
Eli Lilly’s Once-Weekly Diabetes Basal Insulin Onswik Wins EMA Nod
(17h)
Japan Plans $370bn In Public-Private Investment By 2040 To Boost Pharma
(1d)
BIO Notebook: More US FDA Wordplay, Big Pharma Helps Entrances, Biotech M&A Offers Exits
(1d)
340B Reform Bill Could Offer Manufacturers Choice Of Discounts Or Rebates
(1d)
GLP-1 Boom Will Peak in 2026, IRA Brakes Kick In a Year Later, CMS Projects
(1d)
Spain Updates Drug Pricing Rules To Deal With Uncertainty
(1d)
‘Not An Easy Undertaking’: Global Harmonization Challenges A Barrier For NAM Uptake
(1d)
TGA Clarifies How To Comply With Australia’s Prohibition On Prescription Medicines Advertising
(1d)
BIO Notebook: A Post-Mortem On CNPV
(2d)
Innovation Incentives Among Senate Democrats’ Menu Of Drug Pricing Options
(2d)
US FDA Rewrites Effectiveness Playbook, Positions Single-Pivotal-Trial Pathway As New Normal
(2d)
US FDA’s ‘Directed Inspections’ Focus On Most Critical Aspects Of Clinical Trial Conduct
(2d)
BioXconomy
AI cannot fix oncology drug discovery when preclinical models fail to reflect patient tumor biology
(12h)
Saudi drug authority expands US partnerships
(18h)
Clinilabs partners with Rutgers clinical research training
(20h)
Boundless Bio merges with Serapha Bio in $230m deal
(21h)
UK government advisors recommend mAb for type I diabetes treatment
(22h)
RQ Bio raises $115m Series A to advance single-dose flu antibody program
(1d)
‘I'd like it to be our secret’: Why pharma execs are doing business in Korea
(2d)
The reimbursement roadblock: Why cell and gene therapies are struggling to reach patients
(2d)
CEPI provides outbreak modeling to fast-track Bundibugyo ebolavirus vaccine trials
(2d)
Osanni Bio reemerges with $190m Series B after three year build
(2d)
BioArctic signs $800m Lilly deal to break though blood-brain barrier freeze
(3d)
Uncovering the hidden complexities of biopharma deal valuations
(3d)
Study: Digital modeling offers path to more diverse, cost-effective clinical trials
(3d)
Dose of Discovery: Cheng Yi Chen on scaling drugs from lab to launch
(3d)
Celebrating Pride: Spotlighting trailblazing LGBTQ+ scientists
(3d)
AbbVie to acquire Apogee Therapeutics in $10.9bn immunology bet
(4d)
The IPO imperative: Why your biotech needs a seasoned CFO long before the bell rings
(4d)
Biotech and pharma CFO appointments roundup
(4d)
Medable launches AI agent to convert static trial protocols into machine-readable structured data
(4d)
Sanofi opens cold-chain hub for mRNA vaccine and CGT trials
(4d)
BioCentury
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling
(7h)
House committee to vote on China investment and in-licensing restrictions
(9h)
Definium’s $805M offering leads follow-on quartet: Public Equity Report
(9h)
CHMP joins FDA in challenging Tavneos’ approval basis
(10h)
Upcoming FDA adcomms will test post-Makary independence
(11h)
RQ Bio raises $115M to advance long-acting antibody prophylaxis for flu: Venture Report
(1d)
Hengrui rising: Frank Jiang on building a global biotech
(1d)
Tryngolza expansion gives Ionis its first prevalent-market test
(1d)
NewCo boom picks up pace in 1H26
(1d)
Where TrialBlazer puts FDA ahead — and where China still leads
(2d)
Tracking FDA’s TrialBlazer reforms
(2d)
Planned reforms could narrow, but not close, U.S.-China trial start gap
(2d)
Expedition Medicines: Generative covalent chemistry to unlock difficult targets at scale
(2d)
Ebola outbreak exposes treatment gap
(3d)
Retinitis pigmentosa emerges as next genetic medicine test bed
(3d)
R&D leadership changes for Sanofi, Revolution
(3d)
Is legacy tech or the target to blame in Pfizer’s Phase III lung cancer miss?
(3d)
NewCo Serapha taking path to NASDAQ via merger with Boundless: Deals Report
(3d)
FTC pushes back against court’s antitrust standard in J&J biosimilar case
(3d)
AbbVie M&A, FDA reversals, a CAR T first — a BioCentury podcast
(4d)
SCRIP
Viridian’s Lumvoa Puts Pressure On Amgen’s Tepezza In TED
(9h)
BIO 2026: Deals Are Surging Even As Chinese Competition And MFN Concerns Linger
(10h)
Callio Makes The Case For Dual-Payload ADCs
(13h)
Pfizer Discontinues Vizimpro In US Amid Oncologist Preference Shift
(17h)
Encouraging Signs For Revolution’s Pancreatic Cancer Combinations
(17h)
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout
(19h)
Big Pharma Boards Move AI From Strategy Slide To Paycheck
(21h)
Ionis Inks Zilganersen Pact With Recordati To Zero In On US
(21h)
Pivotal Phase II Results Advance HUTCHMED’s Fanregratinib Towards China Approval In ICC
(23h)
Korean Pharma Joins Global AI Boom Amid State Support
(1d)
New Takeda CEO Targets Return To ‘Modest Growth’ Within Three Years
(1d)
BIO Notebook: Big Pharmas Help With Entrances; Biotech M&A Offers Exits
(1d)
Remix Takes RNA-Modulation Approach Public Through Merger With Passage Bio
(1d)
Otsuka Posts Positive Phase IIIb Results For Centanafadine Just Ahead Of PDUFA Date
(1d)
Executives On The Move: Paulo Fontoura To Joining Sanofi And Spearhead Pharma RD
(1d)
Pfizer’s Ibrance Snags Double-Positive Approval As Patent Cliff Looms
(1d)
Europe Must Invest To Stay Globally Relevant, Says Biopharma VC Leader
(1d)
Two Claudin 18.2 ADCs Enter Final Stretch Of Global Race With China NDA
(2d)
BIO Notebook: A Post-Mortem On The CNPV
(2d)
Gilead’s Trodelvy To See Big Boost With First-Line TNBC Approval
(2d)